Seong Wook Kang

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus

Kamini Shah, Won‐Woo Lee, Seung‐Hyun Lee et al. · Arthritis Research & Therapy · 2010 · 292 citations · Full text

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

1,25-Dihyroxyvitamin D3 Promotes <i>FOXP3</i> Expression via Binding to Vitamin D Response Elements in Its Conserved Noncoding Sequence Region

Seong Wook Kang, Sang‐Hyun Kim, Naeun Lee et al. · The Journal of Immunology · 2012 · 194 citations · Full text

3'UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans.

Sunae Ryu, Y. K. Park, Gang Bai et al. · PubMed · 2000 · 147 citations